[go: up one dir, main page]

MX2019001425A - Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea. - Google Patents

Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea.

Info

Publication number
MX2019001425A
MX2019001425A MX2019001425A MX2019001425A MX2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A MX 2019001425 A MX2019001425 A MX 2019001425A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
rosácea
compositions
same
Prior art date
Application number
MX2019001425A
Other languages
English (en)
Other versions
MX389811B (es
Inventor
Roye Olivier
Jacovella Jean
Jomard André
Original Assignee
Nestle Skin Health Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nestle Skin Health Sa filed Critical Nestle Skin Health Sa
Publication of MX2019001425A publication Critical patent/MX2019001425A/es
Publication of MX389811B publication Critical patent/MX389811B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición que comprende un vehículo farmacéuticamente aceptable, al menos un compuesto de la familia de la avermectina y al menos un compuesto antiinflamatorio no esteroideo. La presente invención proporciona, adicionalmente, tal composición para su uso en el tratamiento y/o la prevención de la rosácea.
MX2019001425A 2016-08-04 2017-08-04 Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea MX389811B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16306013 2016-08-04
PCT/EP2017/069809 WO2018024888A1 (en) 2016-08-04 2017-08-04 Compositions and the use thereof for treating or preventing rosacea

Publications (2)

Publication Number Publication Date
MX2019001425A true MX2019001425A (es) 2019-06-10
MX389811B MX389811B (es) 2025-03-20

Family

ID=56618112

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001425A MX389811B (es) 2016-08-04 2017-08-04 Composiciones y el uso de las mismas para el tratamiento o la prevención de la rosácea

Country Status (10)

Country Link
US (1) US10874682B2 (es)
EP (1) EP3493795A1 (es)
JP (1) JP2019523291A (es)
KR (1) KR20190039735A (es)
CN (1) CN109789118B (es)
AU (1) AU2017305853B2 (es)
BR (1) BR112019002213A2 (es)
MX (1) MX389811B (es)
RU (1) RU2738932C2 (es)
WO (1) WO2018024888A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161752B2 (en) * 2019-08-20 2024-12-10 Vishwanath Padmanabhan Compositions and methods for the treatment of anterior blepharitis and posterior blepharitis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
AU2004231323C1 (en) 2003-04-24 2016-11-03 Galderma Holding SA Topical formulation of ivermectin for the treatment of dermatological conditions
US20050147570A1 (en) * 2004-01-06 2005-07-07 Nordsiek Michael T. Methods of administering diclofenac compositions for treating photodamaged skin, rosacea and/or acne
FR2891460B1 (fr) * 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
US20080292560A1 (en) * 2007-01-12 2008-11-27 Dov Tamarkin Silicone in glycol pharmaceutical and cosmetic compositions with accommodating agent
US8541022B2 (en) * 2008-06-02 2013-09-24 Galderma S.A. Method of treating burns using avermectin compound
FR2942138A1 (fr) * 2009-02-16 2010-08-20 Galderma Res & Dev Association de composes pour le traitement ou la prevention des affections dermatologiques
EP2329849B1 (en) * 2009-11-18 2015-04-29 Galderma Research & Development Combination of alpha-2 adrenergic receptor agonist and non-steroidal anti-inflammatory agent for treating or preventing an inflammatory skin disorder
DK2793874T3 (en) * 2011-12-20 2017-02-06 Ectin Res Ab SYNERGISTIC COMBINATON CONTAINING AVERMECTINES AND AN NSAID FOR TUMOR INHIBITION
FR3000397A1 (fr) * 2012-12-31 2014-07-04 Galderma Res & Dev Combinaison de laropiprant et d'ivermectine pour le traitement de la rosacee
US9233117B2 (en) * 2013-07-08 2016-01-12 Galderma S. A. Treatment of inflammatory lesions of rosacea with ivermectin
US20160120797A1 (en) * 2014-10-31 2016-05-05 Sreedhar Rao Rayudu Anti-acne composition and methods of use thereof
WO2016096797A1 (en) * 2014-12-15 2016-06-23 Galderma Sa Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses

Also Published As

Publication number Publication date
RU2019105758A (ru) 2020-09-04
WO2018024888A1 (en) 2018-02-08
CN109789118A (zh) 2019-05-21
MX389811B (es) 2025-03-20
AU2017305853B2 (en) 2023-04-13
CN109789118B (zh) 2022-09-02
AU2017305853A1 (en) 2019-01-31
WO2018024888A8 (en) 2018-06-07
KR20190039735A (ko) 2019-04-15
JP2019523291A (ja) 2019-08-22
RU2019105758A3 (es) 2020-09-10
RU2738932C2 (ru) 2020-12-18
US10874682B2 (en) 2020-12-29
EP3493795A1 (en) 2019-06-12
US20190192545A1 (en) 2019-06-27
BR112019002213A2 (pt) 2019-05-14

Similar Documents

Publication Publication Date Title
ECSP20025899A (es) Compuestos útiles para inhibir a cdk7
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2018003135A1 (es) Derivados aromáticos de sulfonamida.
CL2011000691A1 (es) Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2012003415A1 (es) Compuestos derivados de 2-oxo-piperidina y 1,1-dioxido-tiazina, inhibidores de mdm2; composicion farmaceutica que los comprende; y su uso para el tratamiento del cancer .
SV2017005461A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
MX2016009337A (es) Derivados de azepano y metodos para tratar infecciones por hepatitis b.
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
CL2015003135A1 (es) Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimorficas y métodos de uso.
CL2015000295A1 (es) Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades.
UY33183A (es) Compuestos inhibidores de virus flaviviridae, composición farmaceutica que los contiene y su uso en la manufactura de un medicamento
CL2013000727A1 (es) Compuestos derivados de nucleosidos de imidazo[1,2-f][1,2,4]triazinilo; composicion farmaceutica que los comprende; y su uso para el tratamiento de una infeccion por virus flaviviridae, particularmente infecciones por el virus de la hepatitis c.
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CL2024001565A1 (es) Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso.
CO2018004572A2 (es) Inhibidores de calicreína plasmática humana
CL2015002466A1 (es) Formulaciones de compuestos orgánicos
NI201500175A (es) Compuestos nuevos para el tratamiento del cáncer